Aggressive B-Cell Non-Hodgkin Lymphoma — Trials

Aggressive B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

400 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 115
Recruiting: 56
Ph III recruiting: 1
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (72)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05020392	Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma	unknown	Phase 3	24	Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER	1	Jul 25, 2023	clinicaltrials
NCT03391739	CART-19 Cells For R/R B-ALL(CCFRRBA)	unknown	Phase 2 / Phase 3	20	Fujian Medical UniversityOTHER	1	Jan 5, 2018